AML-related NPM mutations drive p53 delocalization into the cytoplasm with possible impact on p53-dependent stress response

A Holoubek, D Strachotová, P Otevřelová, P Röselová… - Cancers, 2021 - mdpi.com
Simple Summary Nucleophosmin (NPM) is one of the most abundant nucleolar proteins and
its mutations frequently occur in acute myeloid leukemia (AML). The mutations cause …

Non-canonical functions of the gamma-tubulin meshwork in the regulation of the nuclear architecture

M Corvaisier, M Alvarado-Kristensson - Cancers, 2020 - mdpi.com
Simple Summary The appearance of a cell is connected to its function. For example, the
fusiform of smooth muscle cells is adapted to facilitate muscle contraction, the lobed nucleus …

[HTML][HTML] A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic …

D Sohal, S Krishnamurthi, R Tohme, X Gu… - American journal of …, 2020 - ncbi.nlm.nih.gov
Abstract DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to
treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies …

NPM1-mutated acute myeloid leukemia: recent developments and open questions

SS Patel - Pathobiology, 2023 - karger.com
Somatic mutations in the nucleophosmin (NPM1) gene occur in approximately 30% of de
novo acute myeloid leukemias (AMLs) and are relatively enriched in normal karyotype …

ARID3C Acts as a Regulator of Monocyte-to-Macrophage Differentiation Interacting with NPM1

HS Kim, YI Kim, JY Cho - Journal of Proteome Research, 2024 - ACS Publications
ARID3C is a protein located on human chromosome 9 and expressed at low levels in
various organs, yet its biological function has not been elucidated. In this study, we …

Biological effects of BET inhibition by OTX015 (MK-8628) and JQ1 in NPM1-mutated (NPM1c) acute myeloid leukemia (AML)

H Djamai, J Berrou, M Dupont, MM Coudé, M Delord… - Biomedicines, 2021 - mdpi.com
BET inhibitors (BETi) including OTX015 (MK-8628) and JQ1 demonstrated antileukemic
activity including NPM1c AML cells. Nevertheless, the biological consequences of BETi in …

Infrequent Presentations of Chronic NPM1-Mutated Myeloid Neoplasms: Clinicopathological Features of Eight Cases from a Single Institution and Review of the …

S Castaño-Díez, F Guijarro, M López-Guerra… - Cancers, 2024 - mdpi.com
Simple Summary We describe the clinicopathologic features of eight patients with atypical
presentation of NPM1-mutated myeloid neoplasms (MN) and review the literature. Initially …

NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization

M Šašinková, P Heřman, A Holoubek, D Strachotová… - Scientific Reports, 2021 - nature.com
Nucleophosmin (NPM) mutations causing its export from the nucleoli to the cytoplasm are
frequent in acute myeloid leukemia (AML). Due to heterooligomerization of wild type NPM …

Nucleophosmin in leukemia: consequences of anchor loss

B Brodská, M Šašinková, K Kuželová - … journal of biochemistry & cell biology, 2019 - Elsevier
Nucleophosmin (NPM), one of the most abundant nucleolar proteins, has crucial functions in
ribosome biogenesis, cell cycle control, and DNA-damage repair. In human cells, NPM …

A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies

B Hill, D Jagadeesh, B Pohlman, R Dean… - Seminars in …, 2021 - Elsevier
One mechanism by which lymphoid malignancies resist standard apoptosis-intending
(cytotoxic) treatments is genetic attenuation of the p53/p16-CDKN2A apoptosis axis …